Correlation Between Inozyme Pharma and NextCure

Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and NextCure at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and NextCure into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inozyme Pharma and NextCure, you can compare the effects of market volatilities on Inozyme Pharma and NextCure and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of NextCure. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and NextCure.

Diversification Opportunities for Inozyme Pharma and NextCure

0.64

Correlation Coefficient

Inozyme Pharma  NextCure

Poor diversification

The 3 months correlation between Inozyme and NextCure is 0.64. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and NextCure in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NextCure and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with NextCure. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NextCure has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and NextCure go up and down completely randomly.

Pair Corralation between Inozyme Pharma and NextCure

Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the NextCure. In addition to that, Inozyme Pharma is 1.0 times more volatile than NextCure. It trades about -0.27 of its total potential returns per unit of risk. NextCure is currently generating about -0.09 per unit of volatility. If you would invest  149.00  in NextCure on September 2, 2024 and sell it today you would lose (32.00) from holding NextCure or give up 21.48% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Inozyme Pharma  vs.  NextCure

Inozyme Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Inozyme Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

NextCure

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days NextCure has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with Inozyme Pharma and NextCure

The main advantage of trading using opposite Inozyme Pharma and NextCure positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, NextCure can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NextCure will offset losses from the drop in NextCure's long position.

The idea behind Inozyme Pharma and NextCure pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.